Acrivon Q3 net loss $14.5M; cash $142.1M; ACR-368 shows early clinical activity

Acrivon Therapeutics, Inc.

2023-Q3 EPS reported -$1.87

Net loss of $14.5M in Q3 2023 vs $9.2M in Q3 2022; R&D expenses $10.3M, G&A $5.9M.
Cash and marketable securities $142.1M as of Sept 30, 2023; expected to fund operations into H2 2025.
ACR-368: initial clinical activity observed in OncoSignature-positive patients across ovarian, endometrial, urothelial cancers; mature data H1 2024.
ACR-2316 dual WEE1/PKMYT1 inhibitor: IND submission planned Q4 2024; designed for superior single-agent activity via AP3 platform.
Two posters at AACR-NCI-EORTC conference validate ACR-368 OncoSignature assay with 47-58% ORR in tumor biopsies.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Acrivon Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $14.5 million.

Period: the third quarter ended September 30, 2023
Net income: $14.5 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2023 was $14.5 million compared to a net loss of $9.2 million for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-274124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.